{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liang Y"],"funding":["Medical Science and Technology Innovation Project of Chinese Academy of Medical Sciences","Innovation Team in Yunnan Province"],"pagination":["3652-3661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8437489"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(10)"],"pubmed_abstract":["<b>Objective</b>: The aim of the current study was to evaluate immunogenicity and safety levels of human inactivated quadrivalent influenza vaccine (QIV) which includes two A strains (A/H1N1, A/H3N2) and two B lineages (B/Victoria, B/Yamagata) in healthy adults via meta-analysis. <b>Methods</b>: Searches were conducted in PubMed, Cochrane Library, ClinicalTrials.gov, and EMBASE databases published in 2011-2020 according to inclusion and exclusion criteria. The purpose was to collect and perform meta-analysis of related randomized clinical trial (RCT) data concerning safety and immunogenicity levels of human QIV compared with inactivated trivalent influenza vaccine (TIV). <b>Results</b>: A total of 9 literatures were included. There was no significant difference in the seroconversion(SCR) a"],"journal":["Human vaccines & immunotherapeutics"],"pubmed_title":["Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis."],"pmcid":["PMC8437489"],"funding_grant_id":["2016-I2M-3-026","2020-I2M-2-014","2015HC027"],"pubmed_authors":["Jing-Xia G","Guo-Yang L","Ni L","Ma L","Liang Y","Chaolie R","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis.","description":"<b>Objective</b>: The aim of the current study was to evaluate immunogenicity and safety levels of human inactivated quadrivalent influenza vaccine (QIV) which includes two A strains (A/H1N1, A/H3N2) and two B lineages (B/Victoria, B/Yamagata) in healthy adults via meta-analysis. <b>Methods</b>: Searches were conducted in PubMed, Cochrane Library, ClinicalTrials.gov, and EMBASE databases published in 2011-2020 according to inclusion and exclusion criteria. The purpose was to collect and perform meta-analysis of related randomized clinical trial (RCT) data concerning safety and immunogenicity levels of human QIV compared with inactivated trivalent influenza vaccine (TIV). <b>Results</b>: A total of 9 literatures were included. There was no significant difference in the seroconversion(SCR) a","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-04T07:47:53.099Z","creation":"2025-04-04T07:47:53.099Z"},"accession":"S-EPMC8437489","cross_references":{"pubmed":["34156322"],"doi":["10.1080/21645515.2021.1932218"]}}